Monitor the December 4 shareholder vote and any updates on the private placement financing. The CVR milestones for nebokitug in RA will be a key value driver post-merger.
Drug in focus
CMMB drug pipeline →nebokitug
◆ Mixed Named in this press release- Impact
- Phase
- Phase 2 (complete); preparing Phase 3
- Time to market
- At least 4-6 years; Phase 3 PSC trial not yet initiated, and even if successful, filing and approval would follow several years later. The new RA program is even earlier-stage.
- Next catalyst
- None dated
What to watchThe just-announced merger with Scipher Medicine (all-stock, closing Q4 2026) reshapes the investment thesis: pre-merger Chemomab holders get ~32% of the combined entity plus CVRs tied to nebokitug milestones, while the new company will run an AI-guided Phase 2 RA trial. Watch for Phase 3 PSC trial financing clarity post-merger and the merger close vote. The stock already ran ~80% into the deal, much of the near-term re-rating may be priced in.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 2 $1.18entry
- T+1 · 14d ago 0.00%α −0.30% · $1.18
- T+5 · 8d ago +11.02%α +10.94% · $1.31
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Chemomab Therapeutics announced that the SEC declared effective the S-4 registration statement for its proposed merger with Scipher Medicine Corporation. A special shareholder meeting to vote on the merger is scheduled for December 4, 2026, with closing expected in early 2027. Upon closing, pre-merger Chemomab equity holders will own approximately 32% of the combined company and will receive contingent value rights tied to nebokitug milestones.
Key Facts
- SEC declared effective the S-4 registration statement for the Chemomab/Scipher merger on October 30, 2026.
- Special meeting of Chemomab shareholders to vote on the merger is scheduled for December 4, 2026.
- Closing expected in early 2027, subject to shareholder approval, redomiciling to the U.S., and other customary conditions.
- Pre-merger Chemomab equity holders will own approximately 32% of the combined company; Scipher holders will own approximately 68%.
- Chemomab shareholders will receive contingent value rights (CVRs) tied to nebokitug milestones.
- Combined company will be named Scipher Medicine Corporation and trade under ticker SCIP on Nasdaq.
- Shareholders representing ~20% of Chemomab voting power have entered into voting support agreements in favor of the merger.
- Combined company plans to initiate a Phase 2 trial of nebokitug in rheumatoid arthritis in H1 2027, with readout in 2028.
Financial Impact
Pre-merger Chemomab holders to own ~32% of combined company; CVRs provide additional contingent value. No dollar values stated.
Risk Factors
- Shareholder approval not obtained or closing conditions not satisfied.
- Delays in clinical trial initiation or readout for nebokitug.
- Combined company may require additional capital to fund operations and trials.
- Market cap of $9M suggests high risk and volatility; any delay or negative news could have outsized impact.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3393077 |
Track record
15 reports on CMMB
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +33.01% at T+60 after the Aug 19, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13D Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 10, 20266d ago DEFA14A Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $1.18 Now $1.62 +37.29% settles Feb 1
- Nov 2, 202614d ago Press Release Neutral 5/10 Viewing Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
- Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
- Aug 19, 202612w ago 6-K Neutral 6/10 Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
- Aug 19, 202612w ago Press Release Bearish 6/10 Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
- Jul 8, 202618w ago 6-K Bullish 7/10 Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers